Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology, Infectious Disease, and Metabolic Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD147/BSG drug discovery. Below is a curated list of products and related targets to support your assay development.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD147/BSG ECD-Fc Fusion Protein, High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. HEK293 expressed (native glycosylation). | View CD147 Products |
| Gene Delivery | CD147/BSG Lentivirus Particles, Full-length ORF for stable cell line construction. Preserves conformational epitopes. | View CD147 Products |
| Benchmark Ab | Anti-CD147 Recombinant Positive Control. | View CD147 Products |
| Validator | CD147/BSG siRNA Set, For knockdown verification and specificity controls. | View CD147 Products |
| Metabolic Partner | MCT1/SLC16A1 Recombinant Protein, Monocarboxylate transporter complex partner. For binary interaction assays. | View MCT1 Products |
| Amino Acid Partner | CD98hc/SLC3A2 Recombinant Protein, Heavy chain of LAT1 complex. Critical for co-receptor validation. | View CD98hc Products |
| Downstream Effector A | MMP2 Recombinant Protein, Matrix metalloproteinase induced by CD147 signaling. For functional readout assays. | View MMP2 Products |
| Downstream Effector B | MMP9 Recombinant Protein, Downstream effector of tumor invasion. | View MMP9 Products |
Critical Assay Challenges & Specifications
Key technical challenges in CD147/BSG drug discovery and how TarMart products address them.
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse tox evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity. Sequence Verified. |
| MCT1/SLC16A1 co-receptor competition | CD147 ECD-Fc strictly verified by mass spec. Theoretical MW confirmed for binary binding assays. |
| Internalization efficiency (ADC payload delivery) | High-purity ECD-Fc (>95%) with native glycosylation for accurate internalization kinetics. |
| Soluble CD147 (sCD147) shedding quantification | Matched antibody pairs available. Endotoxin controlled (<1 EU/µg) for cell-based assays. |
| Conformational stability | HEK293 expressed (native glycosylation). |
| Lack of controls | Clinical benchmark antibodies (biosimilars) included. |
| False positives / off-target binding | Validated siRNA included for specificity checks. Knockdown verification controls. |
Live CD147/BSG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD147/BSG therapeutics is intensifying, with major players shifting focus from traditional infectious disease applications toward immuno-oncology modalities. As first-generation antibody therapies targeting viral entry (SARS-CoV-2, malaria) transition to Phase II, the next wave of R&D is targeting metabolic reprogramming via the CD147-MCT1 axis and ADC-based solid tumor strategies. Key inflection points include the validation of CD147 as a viable ADC target in triple-negative breast cancer (TNBC) and hepatocellular carcinoma (HCC), where high surface expression correlates with poor prognosis. The emergence of soluble CD147 (sCD147) as a predictive biomarker is driving demand for matched antibody pairs in pharmacodynamic assays. Additionally, first-generation therapies such as Metuximab (Licartin) for HCC have paved the way for next-generation modalities. The future will see a shift from traditional mAbs to ADCs, CAR-T, and bispecifics, along with combination therapies targeting the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotech, Chinese Consortiums | Solid Tumors (TNBC, HCC, NSCLC) | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| mAb / RIT | Chengdu Huashen (Metuximab) | HCC | Binding Affinity (Need native glycosylation) |
| CAR-T | Academic Medical Centers | Glioblastoma, Advanced Solid Tumors, Hematologic Malignancies | Cell Line Construction (Need Lentivirus for stable CD147 overexpression) |
| Bispecific (CD147 x CD3) | Immunotherapy Biotechs | T-Cell Engager Applications | Heterodimer Validation (Need cross-reactive Abs against human/cyno) |
| Blocking mAb | Infectious Disease Programs | Malaria, Viral Entry (SARS-CoV-2) | Receptor Competition Assay (Need full-length CD147 Lentivirus for native conformation) |
| Small Molecule Inhibitor | Discovery Stage | Metabolic Disease | MCT1 Interaction Blockade (Need binary protein-protein interaction assays) |
Molecular Features & Key Mutations
CD147/BSG (Basigin) is a highly glycosylated transmembrane protein belonging to the immunoglobulin superfamily. Its extracellular region contains three Ig-like domains: Ig-like, Ig-like C2-type, and Ig-like V-type (UniProt P35613). These domains mediate interactions with partners such as MCT1, MCT4, and CD98hc. Several natural single nucleotide polymorphisms (SNPs) have been documented: rs201850688, rs11551906, and rs144824657 (VAR_084546–084548). Understanding these features is critical for designing antibodies that avoid off-target effects or metabolic toxicity.
Related Targets
- MCT1 (SLC16A1) – Chaperone partner and metabolic co-regulator.
- MCT4 (SLC16A3) – Another monocarboxylate transporter facilitated by CD147.
- CD98hc (SLC3A2) – Forms a supercomplex with CD147 to regulate amino acid uptake and mTOR signaling.
- MMP2 / MMP9 – Downstream effectors induced by CD147, also responsible for sCD147 shedding.
Using TarMart’s comprehensive toolkit, researchers can accelerate CD147 drug discovery from target validation to preclinical safety assessment.